Robert van der Put | Director Business Development
Intravacc
Robert van der Put holds both a PhD in conjugate vaccine development and a master’s degree in drug innovation and has over 20 years of experience in the vaccine industry. He is a passionate and driven Director of Business Development at Intravacc, a leading CDMO for translational vaccinology. His mission is to advance the development and production of safe and effective vaccines for global health, by leveraging his expertise in vaccine development, process optimization, quality control, and technology transfer.
Appearances:
Pre-Congress Workshops - 21st April @ 10:00
Alternative Vaccine Targets Workshop
-
10am Workshop leaders opening remarks
10.10am Clinical development of vaccines for opioid overdose and allergy
Dr Jay Evans, CSO, InImmune; Director, Center for Translational Medicine, University of Montana
10.30am Advancing a vaccine targeting C9orf72 ALS to the clinical stage
Dr Robert van der Put, Director Business Development, Intravacc
10.50am Adjuvant centric development of overdose preventing vaccines targeting fentanyl
Dr David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital
Dr. Shon Remich, MD, and CMO, Ovax
11.10am Development of adjuvanted vaccines for allergy and Alzheimer’s and drug addiction
Dr Nikolai Petrovsky, Chairman, Vaxine Pty Ltd.
11:30am The potential impact, feasibility and progress in clinical development of senotherapeutics
11:50am Presentation TBC
12:10pm Panel Discussion – Topic TBC What are the unique challenges of getting non-traditional target vaccines to market?
· Ethics of challenge studies
· Regulatory challenges
· Considerations for designing & planning trials
· Funding
All workshop speakers
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events